• 研究室概要
• 主要研究テーマ
• スタッフ
• 主な研究実績
• 主な研究費取得状況

神経免疫学分野では、「ウイルス」「免疫」「神経」の相互作用がどのように神経疾患を引き起こすのかを明らかにし、新しい治療法の開発につなげることを目指しています。特に、九州・鹿児島に多いヒトT細胞白血病ウイルス1型（HTLV-1）感染症と、それにより発症するHTLV-1関連脊髄症（HAM）の克服を重要な目標としています。疾患のメカニズムを多角的な視点から解明し、基礎研究と臨床研究をつなぎながら、地域に根ざした研究を世界へ発信していきます。
神経免疫疾患、ウイルス感染症、臨床と研究をつなぐ研究に興味のある方の参加を歓迎します。

研究室概要

分野サイト

連絡先

主要研究テーマ

スタッフ

教授

研究者総覧 リポジトリ

准教授

研究者総覧 リポジトリ

特任研究員

客員研究員

主な研究実績

野妻智嗣

1. Yoshida T, Nozuma S, Tanaka M, Dozono M, Kodama D, Matsuzaki T, Kondo T, Kubota R, Takashima H. Dimethyl fumarate as a promising therapeutic candidate for virus-associated myelopathy. Brain. 2026:awaf447.
2. Dozono M, Nozuma S, Yoshida T, Kodama D, Matsuzaki T, Matsuura E, Tanaka M, Takashima H, Kubota R. HTLV-1-Infected CD4(+) T Cells Drive Spontaneous Lymphoproliferation and Virus-Specific CD8(+) Cytotoxic T Lymphocyte Expansion in HAM/TSP. Neurol Neuroimmunol Neuroinflamm. 2026;13(4):e200581.
3. Nozuma S, Dozono M, Tanaka M, Kodama D, Yoshida T, Higuchi Y, Sakiyama Y, Matsuura E, Matsuzaki T, Takashima H, Kubota R. HTLV-1-Specific CTL Accumulation in CSF Contributes to Neuroinflammation in HTLV-1-Associated Myelopathy. Neurol Neuroimmunol Neuroinflamm. 2026;13(1):e200508.
4. Dozono M, Nozuma S, Hirakata S, Yoshida T, Kodama D, Tanaka M, Matsuura E, Kubota R, Takashima H. Clinical Characteristics of Parkinsonism in HTLV-1-Associated Myelopathy. Annals of clinical and translational neurology. 2025;12(10):1962-70.
5. Nozuma S, Matsuzaki T, Tanaka M, Kodama D, Dozono M, Yoshida T, Takashima H, Kubota R. T-Cell Receptor/CD3 Downregulation and Impaired Signaling in HTLV-1-Infected CD4+ T Cells of HAM Patients. Int J Mol Sci. 2025;26(4).
6. Nozuma S, Yoshimura A, Pai SC, Chen HJ, Matsuura E, Tanaka M, Kodama D, Dozono M, Matsuzaki T, Takashima H, Yang YC, Kubota R. Geographic characteristics of HTLV-1 molecular subgroups and genetic substitutions in East Asia: Insights from complete genome sequencing of HTLV-1 strains isolated in Taiwan and Japan. PLoS Negl Trop Dis. 2024;18(2):e0011928.
7. Nozuma S, Matsuura E, Tanaka M, Kodama D, Matsuzaki T, Yoshimura A, Sakiyama Y, Nakahata S, Morishita K, Enose-Akahata Y, Jacoboson S, Kubota R, Takashima H. Identification and tracking of HTLV-1-infected T cell clones in virus-associated neurologic disease. JCI Insight. 2023;8(7).
8. Nozuma S, Matsuura E, Tashiro Y, Nagata R, Ando M, Hiramatsu Y, Higuchi Y, Sakiyama Y, Hashiguchi A, Michizono K, Higashi K, Matsuzaki T, Kodama D, Tanaka M, Yamano Y, Moritoyo T, Kubota R, Takashima H. Efficacy of l-Arginine treatment in patients with HTLV-1-associated neurological disease. Annals of clinical and translational neurology. 2023;10(2):237-45.
9. Matsuura E, Nozuma S, Dozono M, Kodama D, Tanaka M, Kubota R, Takashima H. Iliopsoas Muscle Weakness as a Key Diagnostic Marker in HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP). Pathogens. 2023;12(4).
10. Nozuma S, Enose-Akahata Y, Johnson KR, Monaco MC, Ngouth N, Elkahloun A, Ohayon J, Zhu J, Jacobson S. Immunopathogenic CSF TCR repertoire signatures in virus-associated neurologic disease. JCI Insight. 2021;6(4).
11. Nozuma S, Matsuura E, Kodama D, Tashiro Y, Matsuzaki T, Kubota R, Izumo S, Takashima H. Effects of host restriction factors and the HTLV-1 subtype on susceptibility to HTLV-1-associated myelopathy/tropical spastic paraparesis. Retrovirology. 2017;14(1):26.
12. Nozuma S, Matsuura E, Matsuzaki T, Watanabe O, Kubota R, Izumo S, Takashima H. Familial clusters of HTLV-1-associated myelopathy/tropical spastic paraparesis. PLoS One. 9(5):e86144, 2014.

田中正和

1. Tsuchimoto K, Mori A, Tanaka M, Arishima S, Kodama D, Dozono M, Nozuma S, Takashima H, Kubota R. CXCR3/CXCL10 axis-mediated T cell infiltration in the lungs of patients with HTLV-1-associated diseases: implications for subclinical pulmonary involvement. J Med Virol. 98: e70804, 2026.
2. Kurayoshi K, Tanaka M, Nakajima R, Zhou Y, Shirasawa M, Fikriyanti M, Fujisawa JI, Iwanaga R, Bradford AP, Araki K, Ohtani K. Utility of tumor suppressor E2F target gene promoter elements to drive gene expression specifically in cancer cells. Cells. 14: 1953, 2025.
3. Tanaka M, Takenouchi N, Arishima S, Matsuzaki T, Nozuma S, Matsuura E, Takashima H, Kubota R. HLA-A*24 increases the risk of HTLV-1-associated Myelopathy despite reducing HTLV-1 proviral laod. Int J Mol Sci. 25: 6858, 2024.
4. Tanaka M, Yamada M, Mushiake M, Tsuda M, Miwa M. Elucidating differences in early-stage centrosome amplification in primary and immortalized mouse cells. Int J Mol Sci. 25: 383, 2024.
5. Yamashita S, Tanaka M, Ida C, Kouyama K, Nakae S, Matsuki T, Tsuda M, Shirai T, Kamemura K, Nishi Y, Moss J, Miwa M. Physiological levels of poly(ADP-ribose) during the cell cycle regulate Hela cell proliferation. Exp Cell Res. 417: 113163, 2022.
6. Tanaka M, Mushiake M, Takahashi J, Sasaki Y, Yamashita S, Ida C, Masutani M, Miwa M. PARP inhibitor decreases Akt phosphorylation and induces centrosome amplification and chromosomal aneuploidy in CHO-K1 cells. Int J Mol Sci. 23: 3484, 2022.
7. Kodama D, Tanaka M, Matsuzaki T, Nozuma S, Matsuura E, Takashima H, Izumo S, Kubota R. Anti-human T-cell leukemia virus type 1 (HTLV-1) antibody assays in cerebrospinal fluid for the diagnosis of HTLV-1 associated myelopathy/tropical spastic paraparesis. J Clin Microbiol. 59: e03230-20, 2021.
8. Kodama D, Tanaka M, Matsuzaki T, Izumo K, Nakano N, Matsuura E, Saito M, Nagai M, Horiuchi M, Utsunomiya A, Takashima H, Kubota R, Izumo S. Inhibition of ABL1 tyroshine kinase reduces HTLV-1 proviral loads in peripheral blood mononuclear cells from patients with HTLV-1-associated myelopathy/tropical spastic paraparesis. Plos Neg Trop Dis.14: e0008361, 2020.
9. Takenouchi N, Tanaka M, Sato T, Yao J, Fujisawa J, Izumo S, Kubota R, Matsuura E. Expression of TSLC1 in patients with HAM/TSP. J NeuroVirology. 26: 404-414, 2020.
10. Tanaka M, Kawazu Y, Yoshida T, Konishi T, Takenouchi N, Miwa M. Effects of radiation based on whole-body irradiation in HTLV-1-infected mice. J Radiat Res. 60: 710-713, 2019.
11. Yao J, Tanaka M, Takenouchi N, Ren Y, Lee SI, Fujisawa JI. Induction of APOBEC3B cytidine deaminase in HTLV-1-infected humanized mice. Exp Ther Med. 17: 3701-3708, 2019.
12. Tanaka M, Tanaka K, Ida C, Oue A, Yamashita S, Yao J, Takenouchi N, Miwa M. Conflicting effects of poly(ADP-ribose)polymerase inhibitor on cell-mediated and virion-mediated HTLV-1 infection. Virus Res. 270: 197653, 2019.
13. Yamashita S, Tanaka M, Nodono H, Hamada A, Hamada T, Hasegawa M, Nishi Y, Moss J, Miwa M. Human alcohol dehydrogenase 1 is an acceptor protein for polyADP-ribosylation. Biochem Pharmacol. 167: 27-32, 2019.
14. Yamashita S, Tanaka M, Sato T, Ida C, Ohta N, Hamada T, Uetsuki T, Nishi Y, Moss J, Miwa M. Effect of mild temperature shift on poly(ADP-ribose) and γH2AX levels in cultured cells. Biochem.Biophys.Res.Commun. 476: 594-599, 2016.
15. Tanaka M, Sun B, Tezuka K, Fujisawa JI, Tanaka Y, Hoshino H, Miwa M. Neuraminidase enhances the initial steps of human T-cell leukemia virus type 1 replication. Microbes Infect. 12: 119-125, 2010.
    
    

兒玉大介

1.  Kodama D, Tanaka M, Matsuzaki T, Nozuma S, Matsuura E, Takashima H, Izumo S, Kubota R: Anti-Human T-Cell Leukemia Virus Type 1 (HTLV-1) Antibody Assays in Cerebrospinal Fluid for the Diagnosis of HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis. J Clin Microbiol. 59(5):e03230-20, 2021.
2.  Kodama D, Tanaka M, Matsuzaki T, Izumo K, Nakano N, Matsuura E, Saito M, Nagai M, Horiuchi M, Utsunomiya A, Takashima H, Kubota R, Izumo S: Inhibition of ABL1 tyrosine kinase reduces HTLV-1 proviral loads in peripheral blood mononuclear cells from patients with HTLV-1-associated myelopathy/tropical spastic paraparesis. PLoS Negl Trop Dis. 14(7): e0008361, 2020.
3.  Nozuma S, Matsuura E, Kodama D, Tashiro Y, Matsuzaki T, Kubota R, Izumo S, Takashima H: Effects of host restriction factors and the HTLV-1 subtype on susceptibility to HTLV-1-associated myelopathy/tropical spastic paraparesis. Retrovirology 14(1):26, 2017.
4. Kodama D, Saito M, Matsumoto W, Sabouri AH, Izumo S, Arimura K, Usuku K, Bangham CRM, Osame M: Longer dinucleotide repeat polymorphism in matrix metalloproteinase-9 (MMP-9) gene promoter which correlates with higher HTLV-I Tax mediated transcriptional activity influences the risk of HTLV-I associated myelopathy/tropical spastic paraparesis (HAM/TSP). J Neuroimmunol 156(1-2):188-94, 2004.
5. Umehara F, Yamaguchi N, Kodama D, Takenaga S, Kiwaki T, Sonoda Y, Arimura Y, Yamada H, Arimura K, Osame M: Polyneuropathy with minifascicle formation in a patient with 46XY mixed gonadal dysgenesis. Acta Neuropathol 98(3): 309-12, 1999.

有島志保

1. Arishima S, Takahashi M, Dozono M, Yoshida T, Nozuma S, Takashima H, Fujii M, Kubota R. Downregulation of the deubiquitinating enzyme USP10 correlates with neuronal apoptosis in HTLV-1-associated myelopathy. Sci Rep. Jan 23;16(1):6062. 2026
2. Tsuchimoto K, Mori A, Tanaka M, Arishima S, Kodama D, Dozono M, Nozuma S, Takashima H, Kubota R.CXCR3/CXCL10 Axis-Mediated T Cell Infiltration in the Lungs of Patients With HTLV-1- Associated Diseases: Implications for Subclinical Pulmonary Involvement.J Med Virol. Jan;98(1):e70804. 2026
3. Tanaka M, Takenouchi N, Arishima S, Matsuzaki T, Nozuma S, Matsuura E, Takashima H, Kubota R.HLA-A*24 Increases the Risk of HTLV-1-Associated Myelopathy despite Reducing HTLV-1 Proviral Load.Int J Mol Sci. Jun 22;25(13):6858. 2024
4. Xing HQ, Zhang Y, Izumo K, Arishima S, Kubota R, Ye X, Xu Q, Mori K, Izumo S.Decrease of aquaporin-4 and excitatory amino acid transporter-2 indicate astrocyte dysfunction for pathogenesis of cortical degeneration in HIV-associated neurocognitive disorders.Neuropathology. 2017 Feb;37(1):25-34.
5. Sakiyama Y, Kanda N, Higuchi Y, Yoshimura M, Wakaguri H, Takata Y, Watanabe O, Yuan J, Tashiro Y, Saigo R, Nozuma S, Yoshimura A, Arishima S, Ikeda K, Shinohara K, Arata H, Michizono K, Higashi K, Hashiguchi A, Okamoto Y, Hirano R, Shiraishi T, Matsuura E, Okubo R, Higuchi I, Goto M, Hirano H, Sano A, Iwasaki T, Matsuda F, Izumo S, Takashima H.New type of encephalomyelitis responsive to trimethoprim/sulfamethoxazole treatment in Japan.Neurol Neuroimmunol Neuroinflamm. 2015 Aug 13;2(5)
6. Saito M, Tanaka R, Arishima S, Matsuzaki T, Ishihara S, Tokashiki T, Ohya Y, Takashima H, Umehara F, Izumo S, Tanaka Y.Increased expression of OX40 is associated with progressive disease in patients with HTLV-1-associated myelopathy/tropical spastic paraparesis.Retrovirology. 2013 May 7;10:51.

主な研究費取得状況

野妻智嗣

 田中正和

分野サイト